Evofem Biosciences, Inc. (EVFM) Stock Price & Analysis
Evofem Biosciences, Inc. (EVFM) — price $0.004 (-33.33%), as of the Nov 20, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Evofem Biosciences, Inc. · EVFM
Evofem Biosciences, Inc. is a biopharmaceutical company focused on women's sexual and reproductive health.
Price as of Nov 20, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.004 | |
| Change on the day | -33.33% | |
| 52-week range | $0.0008 – $0.014 | |
| Price / earnings (trailing) | 2.21 | |
| Shares traded on the day | 987.8K |
Price & events
Other perspectives
Council score for Evofem Biosciences (EVFM): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Evofem Biosciences (EVFM), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Evofem Biosciences, Inc. (EVFM) is the company analyzed here. It employs 29 people and is led by Saundra Pelletier. In Q3 FY2026 it reported revenue of $5M and net income of $865,000.
What do the latest results show for Evofem Biosciences (EVFM)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $5M. Against analyst estimates the company has EPS beat 8 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $5M | $865,000 | $0.01 (diluted) |
| Q2 FY2026 | $3M | -$11M | -$0.08 (diluted) |
| Q1 FY2026 | $899,000 | -$5M | -$0.04 (diluted) |
| Q4 FY2025 | $10M | $3M | $0.01 (diluted) |
What are the financial strengths and risks for Evofem Biosciences (EVFM)?
Short answer · as of
The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 17.0% · current ratio 0.07 · free-cash-flow yield -75.3%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held EVFM in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported EVFM in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: EVFM Stock
These answers are editorial: 1 of these 1 answer is drawn from the EVFM research dossier (written May 9, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for EVFM?
The main risks for Evofem Biosciences, Inc. include competition from established contraceptive methods, regulatory hurdles and delays, reliance on a single commercial product (Phexxi), and financial risks associated with operating in the biotechnology industry.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com